Genomic newborn screening: ICoNS
Gene: RPS19Comment on list classification: Some challenges identifying variants; deep intronic, large deletions reportedCreated: 21 Apr 2026, 6:46 a.m. | Last Modified: 21 Apr 2026, 6:46 a.m.
Panel Version: 0.37
Accounts for 25-30% of all DBA.
Penetrance seems to be high but incomplete with variable expressivity. Missense variants are less penetrant.
Genetic testing complexities: Deep intronic pathogenic variant c.172+350C>T
More than 90% of the patients present during the first year of life. The diagnosis is generally made at 3 months, of age with a range from birth to adulthood.
Treatment: Corticosteroids and red blood cell transfusions are the mainstays of therapy. Curative treatment - hematopoietic stem cell transplantationCreated: 21 Apr 2026, 2:28 a.m. | Last Modified: 21 Apr 2026, 6:32 a.m.
Panel Version: 0.36
Well established gene-disease association.
Almost complete penetrance for loss of function variants, incomplete penetrance for missense variants. Variable expressivity
The standard of care is corticosteroid treatment, recommended in children at age 12 months or older, and red blood cell transfusions. The only curative therapy is bone marrow transplantation
Sources: Expert ReviewCreated: 10 Feb 2026, 6:52 a.m. | Last Modified: 10 Feb 2026, 6:58 a.m.
Panel Version: 0.29
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
Diamond-Blackfan Anemia
Publications
Variants in this GENE are reported as part of current diagnostic practice
Gene: rps19 has been classified as Green List (High Evidence).
Gene: rps19 has been classified as Green List (High Evidence).
gene: RPS19 was added gene: RPS19 was added to Genomic newborn screening: ICoNS. Sources: Expert Review Mode of inheritance for gene: RPS19 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Publications for gene: RPS19 were set to 20301769; 30503522 Phenotypes for gene: RPS19 were set to Diamond-Blackfan Anemia Review for gene: RPS19 was set to GREEN